132 / 140
Guía OncoSur de sarcomas de partes blandas
132
>
186. Breneman JC, Lyden E, Pappo AS, et al. Prognostic factors and clinical outcomes in children and adolescents
with metastatic rhabdomyosarcoma-a report from the Intergroup Rhabdomyosarcoma Study IV. J Clin Oncol
2003;21:78.
187. Weigel BJ, Lyden E, Anderson JR, et al. Intensive Multiagent Therapy, Including Dose-Compressed Cycles
of Ifosfamide/Etoposide and Vincristine/Doxorubicin /Cyclophosphamide, Irinotecan, and Radiation, in Pa-
tients With High-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group. J Clin Oncol
2016;34:117.
188. Casanova M, Ferrari A, Bisogno G, et al. Vinorelbine and Low-Dose Cyclophosphamide in the Treat-
ment of Pediatric Sarcomas Pilot Study for the Upcoming European Rhabdomyosarcoma Protocol. Cancer
2004;101:1664-71.
189. Bomgaars LR, Bernstein M, Krailo M, et al. Phase II trial of irinotecan in children with refractory solid tumors:
a Children’s Oncology Group Study. J Clin Oncol 2007;25:4622-7.
190. Vassal G, Couanet D, Stockdale E, et al. Phase II trial of irinotecan in children with relapsed or refractory rhab-
domyosarcoma: a joint study of the French Society of Pediatric Oncology and the United Kingdom Children’s
Cancer Study Group. J Clin Oncol 2007;25:356-61.
191. Bisogno G, Riccardi R, Ruggiero A, et al. Phase II study of a protracted irinotecan schedule in children with
refractory or recurrent soft tissue sarcoma. Cancer 2006;106:703-7.
192. Walterhouse DO, Lyden ER, Breitfeld PP, et al. Efficacy of topotecan and cyclophosphamide given in a phase
II window trial in children with newly diagnosed metastatic rhabdomyosarcoma: a Children’s Oncology Group
study. J Clin Oncol 2004;22:1398-403.
193. Saylors 3
rd
RL, Stine KC, Sullivan J, et al. Cyclophosphamide plus topotecan in children with recurrent or
refractory solid tumors: a Pediatric Oncology Group phase II study. J Clin Oncol 2001;19:3463-9.
194. Rapkin L, Qayed M, Brill P, et al. Gemcitabine and Docetaxel (GEMDOX) for the Treatment of Relapsed and
Refractory Pediatric Sarcomas. Pediatr Blood Cancer 2012;59:854-8
Conclusiones y perspectivas futuras
195. Tap WD, Jones RL, Van Tine BA, et al. Olaratumab and doxorubicin versus doxorubicin alone for treatment of
soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. Lancet 2016;388:488-97.
196. Tawbi HA-H, Burgess MA, Crowley J, et al. Safety and efficacy of PD-1 blockade using pembrolizumab in
patients with advanced soft tissue (STS) and bone sarcomas (BS): results of SARC028-a multicenter phase II
study. ASCO Meeting Abstr 2016;34:11006.
197. Paoluzzi L, Ghesani MV, CacavioA, et al. Anti-PD1 therapy with nivolumab in sarcoma. ASCO MeetingAbstr
2016;34:11047.